Reply to the Editor  by John, Ranjit
Circulatory support system as
a bridge to decision in patients
with refractory acute
cardiogenic shock: Is there
a space for extracorporeal
membrane oxygenation?
To the Editor:
We read with interest the timely report by
John and colleagues1 about the elective
use of the Levitronix CentriMag as a bridge
to decision in cardiogenic shock. We com-
mend them for their encouraging results in
12 patients assisted with biventricular
support.
Although the concept of cardiac assis-
tance as bridge to decision is well addressed
by the authors, we believe that extracorpo-
real membrane oxygenation (ECMO) could
play a more valuable role in this context.
This is especially so when the expected as-
sistance time is relatively short (eg, an aver-
age support length of 9.4 days, as reported in
John and colleagues’ experience1).
In our institution, we routinely use both
ECMO and the Levitronix device. The latter
is mainly used for patients with postcardiot-
omy syndrome or primary graft failure; we
advise the use of ECMO in nonsurgical
situations, such as cardiogenic shock after
acute myocardial infarction or failed percu-
taneous coronary interventions.
In this selected group of patients, ECMO
offers some advantages. These include
avoidance of sternotomy and central cannu-
lation, which may cause catastrophic bleed-
ing after aggressive thrombolysis and
antiplatelet treatment, and ease of emer-
gency implantation, even in the intensive
care unit or catheter laboratory, with conse-
quent rapid institution of assistance.
Furthermore, newly designed oxygena-
tors and ECMO circuits (Quadrox Jostra,
Permanent Life Support PLS; MAQUET
GmbH & Co KG, Rastatt, Germany) require
a lower priming volume and present a bio-
inert surface treatment, guaranteeing assis-
tance for an extended 14 days with
a reduced risk of device-related compli-
cations and a less strict anticoagulation
regimen. Moreover, ECMO can be easily
switched to cardiopulmonary bypass at the
time of transplantation or long-term device
implantation.
In our institution, since the beginning
of 2006, the PLS ECMO system has
been extensively used to treat either lung
(6 patients) or cardiac (8 patients) failure
(venovenous and venoarterial cannulation,
respectively). No device failures have been
recorded, even for assistance extending
longer than 60 days.
In our experience, ECMO units are man-
aged by intensive care unit nurses, and ded-
icated personnel are usually not required.
Activated thromboplastin time is kept
between 40 and 50 seconds, with a level of
antithrombin III activity greater than 80%.
In cases of bleeding, we have withheld
heparin for more than 30 hours without
any thrombotic events.
Leg ischemia, related to common femo-
ral artery cannulation, is the complication
we have seen most frequently. In most cases,
however, this condition can be resolved by
cannulating the superficial femoral artery
as well with a small perfusion cannula.
In conclusion, although the many advan-
tages offered by the Levitronix pump are
remarkable, patient-tailored assistance can
be achieved for selected candidates with
new versions of ECMO systems, such as
the PLS. Thanks to modern technology,
these systems couple ease of implantation
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Letters to the EditorReply to the Editor:
I appreciate the comments of Santise and
colleagues regarding the role of extracorpo-
real membrane oxygenation (ECMO) in the
care of patients with refractory cardiogenic
shock. Clearly, ECMO has been, and will
probably always remain, a useful treatment
in the ever-changing armamentarium op-
tions for this critically ill group. It is still
the primary option for pediatric patients,
but the frequency of its use for adults hasThe Journal of Thoracic and Cardiovascubeen significantly reduced thanks to im-
proved short-term ventricular support de-
vices (eg, CentriMag, Abiomed). Such
devices provide more reliable support, with
markedly improved durability with respect
to the Bio-Medicus systems, the first gener-
ation of short-term ventricular assist devices.
ECMO certainly offers the advantage of
avoiding a median sternotomy, as well as
the opportunity for rapid institution of sup-
port in the catheterization laboratory and
the intensive care unit, as Santise and col-
leagues report. The use of ECMO is limited,
however, by its main drawbacks: limited
durability and significant neurologic and
peripheral vascular complications. The
incidence of such complications may be af-
fected by technologic advances in the design
of ECMO circuits and oxygenators or by
altered peripheral cannulation techniques.
Several published studies, some involving
pediatric patients, have looked at the use
of ECMO for a wide range of indications
(eg, graft failure after lung transplantation,
right ventricular failure after heart transplan-
tation, postcardiotomy assistance, resuscita-
tion after cardiac arrest, and bridge to bridge
support for cardiogenic shock). All these
series reported a mean ECMO duration of
about 4 days or less.1-5 In one large, experi-
enced single-center series, the complica-
tions during ECMO were as follows:
infectious, 49%; renal failure requiring dial-
ysis, 40%; neurologic, 33%; and limb com-
plications, 25%.2 Of course, not all such
complications are related to ECMO itself.
Instead, they often are a result of the critical
condition of a patient with multiorgan dys-
function. Further, all such complications
(with the relative exception of limb compli-
cations) can also potentially occur with
short-term ventricular assist devices.
In conclusion, I agree with Santise and
colleagues that there is definitely a place
for ECMO in the treatment of patients with
acute cardiogenic shock. In the near future,
we do not know what the interplay will be
between surgical and percutaneous devices,
including ECMO. Until then, it remains im-
perative that we continue to be innovative,
open-minded, and aggressive, continually
striving to improve outcomes for this criti-
cally ill group of patients.
Ranjit John, MD
Division of Cardiothoracic Surgery
University of Minnesota
Minneapolis, MN 55455lar Surgery c Volume 135, Number 3 717
pneumonectomy, higher incidences have
been reported for empyema, bronchopleural
fistula, and adult respiratory distress syn-
drome than are seen after standard resection
without induction therapy.3
Uy and colleagues1 referred to European
Organization for Research and Treatment of
Cancer trial 08941, results of which were
recently reported.3,4 In this multicenter trial,
patients with histologically proven stage
IIIA-N2 non–small cell lung cancer were
treated with induction chemotherapy—
without radiotherapy—and in case of
response were subsequently randomly as-
signed to undergo either surgery or radio-
therapy. Pneumonectomy was performed in
46.8% of patients; the 30-day mortality in
this subgroup was 6.9%, which was much
lower than those reported by Uy and col-
leagues1 and in the INT-0139 trial.2 Similar
results as in the EORTC 08941 study were
recently published by a group from Stras-
bourg; they reported a 30-day mortality of
6.7% in a series of 60 patients under-
going pneumonectomy after induction
chemotherapy.5
Although Uy and colleagues1 did not
specifically comment on this issue, the
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Reply to the Editor:
Dr Van Schil’s letter clearly enunciates the
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chemotherapy alone in stage
IIIA-N2 non–small cell lung
cancer
To the Editor:
I read with great interest the recent article
of the Toronto group on improved results
of induction chemoradiation followed by sur-
gery for selected patients with stage IIIA-N2
non–small cell lung cancer.1 Uy and col-
leagues1 are to be congratulated for their
detailed analysis and honest data reporting
regarding this difficult subset of patients
with N2 disease for whom the optimal treat-
ment remains to be defined. As in the Inter-
group-0139 trial,2 Uy and colleagues1
adopted an induction therapy of concurrent
chemotherapy and radiotherapy, followed
by surgical resection if there was no progres-
sive disease on restaging. In 11 cases
(27.5%), pneumonectomy was necessary.
As previously observed in the INT-0139 trial,
mortality in this setting was high: 27% over-
all, and even 50% for complex pneumonecto-
mies. Causes of death were adult respiratory
distress syndrome and postoperative hemor-
rhage. After induction therapy followed by
type of induction therapy—chemotherapy
versus combined chemoradiotherapy—
may be important in explaining this mortal-
ity difference. Unfortunately, there are no
randomized studies directly comparing in-
duction chemotherapy with chemoradio-
therapy with respect to outcome after
surgical resection for locally advanced
non–small cell lung cancer.
Although a pneumonectomy can be
safely performed after induction chemother-
apy, it remains a high-risk procedure after
induction chemoradiotherapy, especially
when a complex procedure has to be per-
formed on the right side. Coverage of the
bronchial stump with viable tissue is essen-
tial to prevent the dreadful complication of
bronchial stump dehiscence.
Paul E. Van Schil, MD, PhD
Department of Thoracic and Vascular Surgery
University Hospital of Antwerp
Antwerp, Belgium
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concern of many surgeons that the combina-
tion of chemotherapy and radiation for in-
duction increases the risk of subsequent
surgical intervention, whereas the use of
induction chemotherapy alone does not.
Although the report from Martin and
colleagues,1 as well as the data from the In-
tergroup 0139 trial,2 support this concern,
we believe this not to be the case. In our ex-
perience, as outlined in our report, the mor-
talities all occurred early in our experience
with this protocol. There were no mortalities
in the last 34 patients, including those
undergoing pneumonectomy. In doing the
chart audit, we noted that the mortalities in
the patients undergoing pneumonectomy
occurred in patients with large, bulky central
tumors, in whom the hilar dissection could
be anticipated to be difficult. In retrospect,
we would now not consider such patients
for resection. Based on our own experience,
we do not think that induction chemoradia-
tion results in excessive risk for resection
if patients are selected appropriately. Fur-
thermore, this is supported by the work of
Sonett and colleagues,3 who used even
higher doses of radiation without any oper-
ative mortality.
In selecting patients for trimodality ther-
apy, we believe that both the primary and
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